All biologic classes | IL-17 | IL-12/23 | TNF | |
Total cohort | ||||
Number of treatment episodes | 11 560 | 2148 | 2882 | 6530 |
Total person-years of follow-up | 9264 | 1528 | 2461 | 5275 |
Incident serious infections, n (%) | 190 (2) | 32 (1) | 32 (1) | 126 (2) |
Incidence rate (95% CI), per 100 person-years | 2.1 (1.8 to 2.4) | 2.1 (1.5 to 2.9) | 1.3 (0.9 to 1.8) | 2.4 (2.0 to 2.8) |
PsO | ||||
Number of treatment episodes | 9691 | 1903 | 2644 | 5144 |
Total person-years of follow-up | 8010 | 1406 | 2311 | 4293 |
Incident serious infections, n (%) | 156 (2) | 26 (1) | 29 (1) | 101 (2) |
Incidence rate (95% CI), per 100 person-years | 2.0 (1.7 to 2.3) | 1.9 (1.2 to2.7) | 1.3 (0.9 to 1.8) | 2.4 (1.9 to 2.8) |
PsA | ||||
Number of treatment episodes | 5517 | 944 | 888 | 3685 |
Total person-years of follow-up | 4159 | 605 | 647 | 2907 |
Incident serious infections, n (%) | 105 (2) | 14 (1) | 13 (1) | 78 (2) |
Incidence rate (95% CI), per 100 person-years | 2.5 (2.1 to 3.1) | 2.3 (1.3 to 3.7) | 2.0 (1.1 to 3.3) | 2.7 (2.1 to 3.3) |
Biologic-naïve | ||||
Number of treatment episodes | 5995 | 332 | 1344 | 4319 |
Total person-years of follow-up | 5019 | 237 | 1217 | 3565 |
Incident serious infections, n (%) | * | * | 11 (1) | 80 (2) |
Incidence rate (95% CI), per 100 person-years | 2.0 (1.6 to 2.4) | 3.4 (1.6 to 6.3) | 0.9 (0.5 to 1.6) | 2.2 (1.8 to 2.8) |
Biologic experienced | ||||
Number of treatment episodes | 5565 | 1816 | 1538 | 2211 |
Total person-years of follow-up | 4.246 | 1292 | 1244 | 1710 |
Incident serious infections, n (%) | 91 (2) | 24 (1) | 21 (1) | 46 (2) |
Incidence rate (95% CI), per 100 person-years | 2.1 (1.7 to 2.6) | 1.9 (1.2 to 2.7) | 1.7 (1.1 to 2.5) | 2.7 (2.0 to 3.5) |
*Clinical description of cells with 10 or fewer observations suppressed per data license.
IL, interleukin; TNF, tumour necrosis factor.